We also speculate that clinicians favoured SGLT2 inhibitors in patients with hypertension and obesity in this real‐world setting, after considering the effects of SGLT2 inhibitors on lowering blood pressure and body weight reported in international studies31 and in Japanese studies.32, 33 Clinicians might also be delaying SGLT2 inhibitors owing to potential concern about safety.34 These differences in baseline characteristics should be considered when interpreting data from real‐world clinical practice. The gene discussed is SLC5A2; the disease is obesity due to melanocortin 4 receptor deficiency.